Sana Biotechnology, Inc. 8-K

What Happened Sana Biotechnology, Inc. filed an 8-K on April 24, 2026 announcing that on April 22, 2026 Dr. Steven D. Harr tendered his resignation as a Class I director and was immediately re-appointed as a Class III director. The change was made solely to rebalance the Board’s three classes under the company’s Amended and Restated Certificate of Incorporation; Dr. Harr’s service on the Board is treated as uninterrupted.

Key Details

• Filing: Form 8-K filed April 24, 2026 (Item 5.02 — director changes).
• Director: Steven D. Harr, M.D., moved from Class I (term previously expiring at the 2028 annual meeting) to Class III (term now expiring at the 2027 annual meeting).
• Board composition: After the change the Board has three directors in each of Class I, II, and III.
• Reason: Action taken solely to achieve a more equal balance of director membership among the three classes to comply with the Certificate of Incorporation.

Why It Matters This is a procedural governance change—no director left the Board and no new directors were added. For investors, the update affects board class assignments and the timing of when directors’ seats are up for election (2027 vs. 2028), but does not indicate changes to management or company strategy. The filing confirms compliance with the company’s governing charter rather than signaling operational developments.